Osiris Therapeutics, Inc. Schedules Conference Call to Provide Update on its Grafix® Diabetic Foot Ulcer Trial

Published: Aug 13, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that C. Randal Mills, Ph.D., President and Chief Executive Officer, will host a conference call to discuss the results of the interim analysis of its multicenter, randomized, controlled trial evaluating the efficacy and safety of Grafix® for the treatment of chronic diabetic foot ulcers. The call will be held tomorrow, August 13, 2013 at 9:00 a.m. ET.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news